Caricamento...
MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC
BACKGROUND: PARP inhibitors have been the most promising target drugs with widely proven benefits among ovarian cancer patients. Although platinum-response, HR-related genes, or HRD genomic scar detection are acceptably used in assessment of Olaparib response, there are still evident limitations in...
Salvato in:
| Pubblicato in: | J Hematol Oncol |
|---|---|
| Autori principali: | , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6995078/ https://ncbi.nlm.nih.gov/pubmed/32005272 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-0844-0 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|